We are live on ! Find out more
MYGN icon

Myriad Genetics
MYGN

221 hedge funds and large institutions have $640M invested in Myriad Genetics in 2025 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 75 increasing their positions, 71 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

586% more call options, than puts

Call options by funds: $954K | Put options by funds: $139K

33% more capital invested

Capital invested by funds: $480M → $640M (+$159M)

11% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 37

6% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 71

0% more funds holding

Funds holding: 221 → 221 (0)

3.03% less ownership

Funds ownership: 98.15% → 95.13% (-3%)

Holders
221
Holders Change
–
Holders Change %
0%
% of All Funds
2.9%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
41
Increased
75
Reduced
71
Closed
37
Calls
$954K
Puts
$139K
Net Calls
+$815K
Net Calls Change
-$1.53M

Top Buyers

Rank Fund Capital Flow
1
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$8.86M
2
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$5.81M
3
AG
Algert Global
California
+$5.42M
4
Goldman Sachs
Goldman Sachs
New York
+$5.16M
5
RA
Royce & Associates
New York
+$3.98M

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$8.16M
2
Citadel Advisors
Citadel Advisors
Florida
-$6.76M
3
KLP
Kent Lake PR
Puerto Rico
-$6.64M
4
PCM
Portolan Capital Management
Massachusetts
-$6.18M
5
Morgan Stanley
Morgan Stanley
New York
-$5.56M
Name Holding Trade Value Shares
Change 		Change in
Stake
RA
26
Royce & Associates
New York
$4.84M +$3.98M +670,000 New
Aberdeen Group
27
Aberdeen Group
United Kingdom
$4.62M +$2.43M +409,460 +178%
VPC
28
Vestal Point Capital
New York
$4.34M +$3.56M +600,000 New
Bank of New York Mellon
29
Bank of New York Mellon
New York
$4.23M -$238K -40,164 -6%
Citadel Advisors
30
Citadel Advisors
Florida
$4.14M -$6.76M -1,138,871 -67%
JP Morgan Chase
31
JP Morgan Chase
New York
$3.99M -$673K -113,338 -17%
Ameriprise
32
Ameriprise
Minnesota
$3.93M +$752K +126,630 +30%
CSS
33
Cubist Systematic Strategies
Connecticut
$3.84M +$1.57M +265,174 +100%
Wells Fargo
34
Wells Fargo
California
$3.67M +$472K +79,477 +19%
AFM
35
Anson Funds Management
Texas
$3.65M -$5M -841,938 -63%
Invesco
36
Invesco
Georgia
$3.58M +$36.2K +6,104 +1%
UBS Group
37
UBS Group
Switzerland
$3.56M -$1.81M -304,348 -38%
Bank of America
38
Bank of America
North Carolina
$3.53M +$427K +71,956 +17%
Principal Financial Group
39
Principal Financial Group
Iowa
$3.25M -$45.9K -7,735 -2%
Nordea Investment Management
40
Nordea Investment Management
Sweden
$2.97M +$78.9K +13,281 +3%
AE
41
AMH Equity
New York
$2.89M +$594K +100,000 +33%
Walleye Capital
42
Walleye Capital
New York
$2.89M +$2.1M +354,385 +779%
Deutsche Bank
43
Deutsche Bank
Germany
$2.89M +$2.04M +342,820 +605%
TI
44
Trexquant Investment
Connecticut
$2.89M +$2.37M +399,292 New
Fidelity Investments
45
Fidelity Investments
Massachusetts
$2.88M +$294K +49,512 +14%
BNP Paribas Financial Markets
46
BNP Paribas Financial Markets
France
$2.78M +$746K +125,676 +49%
SPS
47
Susquehanna Portfolio Strategies
Pennsylvania
$2.77M -$430K -72,483 -16%
Public Sector Pension Investment Board (PSP Investments)
48
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$2.62M +$289K +48,691 +15%
Two Sigma Advisers
49
Two Sigma Advisers
New York
$2.41M +$270K +45,400 +16%
Canada Pension Plan Investment Board
50
Canada Pension Plan Investment Board
Ontario, Canada
$2.23M – – –
1
2
3 4 5

MYGN Hedge Fund Activity: Q3 2025 in Review

221 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q3 2025, worth a combined $640M — up 33% from $480M a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new MYGN positions and 37 closed out — a net gain of 4 holders — while 75 added to existing stakes and 71 trimmed.

The largest buyer was Jacobs Levy Equity Management, adding an estimated $8.86M. The largest seller was Vanguard Group, cutting an estimated $8.16M.

  • 221 institutional investors held Myriad Genetics (MYGN) as of Q3 2025, unchanged from Q2 2025.
  • Funds reported $640M of Myriad Genetics stock for Q3 2025, up 33% quarter-over-quarter.
  • 41 funds opened new Myriad Genetics positions in Q3 2025 and 37 closed out, a net change of +4 holders.
  • The largest Myriad Genetics buyer in Q3 2025 was Jacobs Levy Equity Management, an estimated $8.86M added.
  • The largest Myriad Genetics seller in Q3 2025 was Vanguard Group, an estimated $8.16M sold.

Based on aggregated 13F filings for Q3 2025.